Results 91 to 100 of about 18,791 (142)
Some of the next articles are maybe not open access.
Journal of Pharmacology and Experimental Therapeutics, 1999
The neurotrophic property of the immunosuppressant drug FK506 (tacrolimus) is believed to depend on the 12-kDa FK506-binding protein (FKBP-12). Here, we show that FK506 maintains its neurotrophic activity in primary hippocampal cell cultures from FKBP-12 knockout mice.
Weinian Shou +2 more
exaly +3 more sources
The neurotrophic property of the immunosuppressant drug FK506 (tacrolimus) is believed to depend on the 12-kDa FK506-binding protein (FKBP-12). Here, we show that FK506 maintains its neurotrophic activity in primary hippocampal cell cultures from FKBP-12 knockout mice.
Weinian Shou +2 more
exaly +3 more sources
Journal of Controlled Release, 1999
A novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate, was developed and its physico-chemical, biological and pharmacokinetic characteristics were studied. The conjugate was estimated to contain 0.45% of FK506 and the coupling molar ratio was approximately 1:1 (dextran-FK-506).
Mitsuru Hashida +2 more
exaly +3 more sources
A novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate, was developed and its physico-chemical, biological and pharmacokinetic characteristics were studied. The conjugate was estimated to contain 0.45% of FK506 and the coupling molar ratio was approximately 1:1 (dextran-FK-506).
Mitsuru Hashida +2 more
exaly +3 more sources
The mechanism of action of cyclosporin A and FK506
Immunology Today, 1992CsA and FK506 are powerful suppressors of the immune system, most notably of T cells. They act at a point in activation that lies between receptor ligation and the transcription of early genes. Here, Stuart Schreiber and Gerald Crabtree review recent findings that indicate CsA and FK506 operate as prodrugs: they bind endogenous intracellular receptors,
S L, Schreiber, G R, Crabtree
openaire +2 more sources
Oral Absorption of FK506 in Rats
Pharmaceutical Research, 1993The oral absorption of FK506 in solid dispersion formulation was studied in rats. The obtained area under the concentration versus time curve (AUC) increased in a nonlinear fashion with a small dose-dependent increase in the peak blood concentrations (Cmax).
A, Kagayama +7 more
openaire +2 more sources
Molecular and Biochemical Parasitology, 2005
We have identified an immunophilin of the FKBP family in Plasmodium falciparum that contains a conserved peptidyl prolyl isomerase (PPIase) and tetratricopeptide repeat (TPR) domains. The 35 kDa protein was named FKBP35 and expressed in bacteria. Recombinant FKBP35 exhibited potent PPIase and protein folding activities against defined substrates in ...
Rajinder, Kumar +4 more
openaire +2 more sources
We have identified an immunophilin of the FKBP family in Plasmodium falciparum that contains a conserved peptidyl prolyl isomerase (PPIase) and tetratricopeptide repeat (TPR) domains. The 35 kDa protein was named FKBP35 and expressed in bacteria. Recombinant FKBP35 exhibited potent PPIase and protein folding activities against defined substrates in ...
Rajinder, Kumar +4 more
openaire +2 more sources
Crystal Structure of the FK506 Binding Domain of Plasmodium falciparum FKBP35 in Complex with FK506
Biochemistry, 2008The emergence of multi-drug-resistant strains of Plasmodium parasites has prompted the search for alternative therapeutic strategies for combating malaria. One possible strategy is to exploit existing drugs as lead compounds. FK506 is currently used in the clinic for preventing transplant rejection.
Ye, H +7 more
openaire +5 more sources
FK506 Treatment of Noninfectious Uveitis
American Journal of Ophthalmology, 1994We studied the clinical effects of the immunosuppressive agent FK506 in patients with noninfectious uveitis.This study was designed as a multicenter open clinical trial in Japan. Sixteen patients with noninfectious uveitis who had visited the Uveitis Survey Clinic of the Yokohama City University Hospital were given FK506.
M, Ishioka +6 more
openaire +2 more sources
Evaluation of Synthetic FK506 Analogues as Ligands for the FK506-Binding Proteins 51 and 52
Journal of Medicinal Chemistry, 2012The FK506-binding proteins (FKBP) 51 and 52 are cochaperones that modulate the signal transduction of steroid hormone receptors. Both proteins have been implicated in prostate cancer. Furthermore, single nucleotide polymorphisms in the gene encoding FKBP51 have been associated with a variety of psychiatric disorders.
Ranganath, Gopalakrishnan +6 more
openaire +2 more sources
The nephrotoxicity of FK506 as compared with cyclosporine
Current Opinion in Nephrology and Hypertension, 1993FK506, a new macrolide immunosuppressant agent, is approximately 100 times more potent than cyclosporine. Early clinical trials demonstrated FK506 to be effective in reversing refractory rejection in liver, kidney, and heart transplantation. Like cyclosporine, FK506 has significant nephrotoxicity.
openaire +2 more sources
Cardiovascular Pathology, 2003
Abstract Introduction: Whether FK506 or cyclosporin is better for chronic immunosuppression in heart transplant patients has been debated. We examined endomyocardial biopsies from patients treated with these two drugs to determine if there was a difference in frequency of histologic cellular rejection episodes and Quilty lesions. The Quilty lesion (
Nupoor A. Gajjar +4 more
openaire +1 more source
Abstract Introduction: Whether FK506 or cyclosporin is better for chronic immunosuppression in heart transplant patients has been debated. We examined endomyocardial biopsies from patients treated with these two drugs to determine if there was a difference in frequency of histologic cellular rejection episodes and Quilty lesions. The Quilty lesion (
Nupoor A. Gajjar +4 more
openaire +1 more source

